文献速递白血病淋巴瘤

LEF1蛋白水平升高及异构体转换驱动慢性淋巴细胞白血病细胞增殖

Increased LEF1 protein levels and isoform switching drive cell proliferation in chronic lymphocytic leukemia.
PubMed 文献 · Blood · 2025-01-01

该研究对慢性淋巴细胞白血病(CLL)患者样本进行功能分析,发现侵袭性疾病中LEF1蛋白稳定性增强导致蛋白水平升高,且LEF1外显子6跳跃异构体在增殖性CLL中富集,通过结合并诱导细胞周期和代谢基因网络驱动增殖,而全长LEF1促进静息基因特征并限制白血病生长。

要点

  • LEF1蛋白水平而非mRNA水平在临床侵袭性CLL中升高,源于蛋白稳定性增强。
  • LEF1蛋白丰度受淋巴结来源刺激(T细胞相互作用和B细胞受体信号)选择性调节。
  • LEF1外显子6跳跃异构体在增殖性和侵袭性CLL中富集,驱动增殖;全长LEF1限制白血病生长。

核心结论

  • LEF1是CLL中的致癌转录因子,其生物学和临床效应受蛋白丰度和异构体组成的转录后调控。

研究设计与样本

  • 研究使用患者来源样本进行广泛功能分析,对CLL中LEF1功能进行综合机制剖析,并进行体外和体内实验。

主要发现

  • 尽管LEF1信使RNA水平保持稳定,临床侵袭性疾病患者因蛋白稳定性增强而显示LEF1蛋白水平升高。
  • LEF1蛋白丰度受淋巴结来源刺激(包括T细胞相互作用和B细胞受体信号)选择性调节。
  • 低LEF1蛋白(惰性疾病特征)支持B细胞活化,而侵袭性疾病中蛋白丰度增加通过结合并诱导细胞周期和代谢基因网络促进增殖。
  • LEF1外显子6跳跃在增殖性和侵袭性CLL中富集,体外和体内实验显示LEF1驱动的增殖由这些短的可变剪接异构体介导。
  • 所有LEF1异构体结合核心增殖和活化相关基因,但诱导不同转录程序:全长LEF1促进静息基因特征并限制白血病生长,而外显子6跳跃异构体驱动增殖。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The transcription factor lymphoid enhancer-binding factor 1 (LEF1) is aberrantly expressed across all subtypes and stages of chronic lymphocytic leukemia (CLL), yet the molecular mechanisms underlying its contribution to CLL pathogenesis remain poorly defined. Here, we conducted a comprehensive mechanistic dissection of LEF1 function in CLL using extensive functional analyses of patient-derived samples. We identified that, although LEF1 messenger RNA levels remain stable, patients with clinically aggressive disease show elevated LEF1 protein levels due to enhanced protein stability. LEF1 protein abundance is selectively modulated by lymph node-derived stimuli, including T-cell interactions and B-cell receptor signaling. Importantly, we uncovered a dual, context-dependent role for LEF1 that is determined by its protein levels. Low LEF1 protein, characteristic of indolent disease, supports B-cell activation, whereas increased protein abundance in aggressive disease promotes proliferation through the binding and induction of cell cycle and metabolic gene networks. We further showed that LEF1 exon 6 skipping is enriched in proliferative and aggressive CLL. Both in vitro and in vivo experiments revealed that LEF1-driven proliferation is mediated by these short, alternative spliced isoforms. Although all LEF1 isoforms bind to a core set of proliferation- and activation-related genes, they induce distinct transcriptional programs; full-length LEF1 promotes a quiescence gene signature and limits leukemic growth, whereas exon 6-skipping isoforms drive proliferation. Our findings establish LEF1 as an oncogenic transcription factor in CLL whose biological and clinical effects are modulated posttranscriptionally by both protein abundance and isoform composition.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Mateos-Jaimez J, Vidal-Crespo A, Charalampopoulou S, et al. Increased LEF1 protein levels and isoform switching drive cell proliferation in chronic lymphocytic leukemia. Blood. 2025. PMID: 40983031. doi:10.1182/blood.2025030129

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。